Slide 1: OraSure Investor Update
OraSure Investor Update FEBRUARY 2026
Slide 2: Disclaimers
Disclaimers Forward-Looking Statements: This presentation of OraSure Technologies, Inc. (the “Company” or “OraSure”) contains certain “forward-looking statements” within the meaning of federal securities laws, including with respect to products, product candidate development and manufacturing activi
Slide 3: Disciplined execution driving stronger platform for growth
Disciplined execution driving stronger platform for growth Three years of progress in transformation strategy Strengthen Elevate Accelerate our Foundation our Core Growth our Profitable Growth Return core business to breakeven; Drive core growth and profitability; Execute focused strategy to drive c
Slide 4: Financial performance summary
Financial performance summary Innovating and operating with disciplined execution and accountability Q4 results Q1 guidance • Total Revenue: $26.8 million • Total Revenue: $26 to $29 million • Core Revenue: $26.7 million • Non-GAAP Gross Margin: 41.4% • Non-GAAP Gross Margin: low 40% range External
Slide 5: Clear strategy to innovate and accelerate growth with near-term catalysts
Clear strategy to innovate and accelerate growth … with near-term catalysts in attractive markets Delivering our near-term Expanding our long-term product roadmap innovation pipeline Plan to launch differentiated innovation Leveraging OTI strengths to compete and by executing on near-term milestones
Slide 6: Product roadmap: anticipated near-term milestones
Product roadmap: anticipated near-term milestones Protein-specific blood Blood self-collection; At-home first-void urine Disposable molecular dx, Description collection & sample self-collection rapid test Dot = dried blood spot vs. stabilization capillary blood draw Global market $ $700M $500M $1.5B
Slide 7: Segment attractiveness
Expanding our pipeline in high-value growth markets Illustrative examples leveraging OTI strengths High OTI strengths Example Liquid biopsy STIs • Chemistries for sample Segment attractiveness criteria: stabilization, transport, and Market size storage Wellness Infectious disease • Expertise in oral
Slide 8: OraSure today: stronger, focused, and executing for sustainable growth
OraSure today: stronger, focused, and executing for sustainable growth Strengthen Elevate Accelerate our Foundation our Core Growth our Profitable Growth OTI Proprietary 8 © 2026 OraSure Technologies, Inc.
Slide 9: Appendix
Appendix © 2026 OraSure Technologies, Inc. 9
Slide 10: Reconciliation of Non-GAAP Gross Margin
Reconciliation of Non-GAAP Gross Margin OraSure Technologies GAAP to Non-GAAP Reconciliation ($ in 000's) For the Three Months Ended For the Years Ended December 31, December 31, 2025 2024 2025 2024 Net Revenues $ 26,763 $ 37,445 $ 115,021 $ 185,827 GAAP Cost of Products and Services Sold 15,795 23,